Stephen Abreu

Feb 27, 2024 | lexology.com | Sharon Flanagan |Stephen Abreu |Robert Darwin |Carlton Fleming |Frank Rahmani |Meenakshi Datta | +3 more

Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance. Regulatory developments in the U.S.: The FDA has issued several new policy documents on issues such as clinical trial design and conduct, affirming the agency’s high bar for approvals.

Nov 9, 2023 | datamatters.sidley.com | Stephen Abreu

Artificial Intelligence (AI) has the potential to revolutionize how we find, develop, and deliver new life-saving therapies. Join “State of the Art” host and Sidley partner Stephen Abreu as he speaks with Colin Hill, CEO and Co-Founder of Aitia. Together, they discuss the challenges and opportunities AI presents for the pharmaceutical industry, particularly how AI is accelerating the pace of drug discovery and its implications for the future of medicine.

Nov 9, 2023 | lexology.com | Stephen Abreu

Click here to watch the videoArtificial Intelligence (AI) has the potential to revolutionize how we find, develop, and deliver new life-saving therapies. Join “State of the Art” host and Sidley partner Stephen Abreu as he speaks with Colin Hill, CEO and Co-Founder of Aitia. Together, they discuss the challenges and opportunities AI presents for the pharmaceutical industry, particularly how AI is accelerating the pace of drug discovery and its implications for the future of medicine.

Nov 1, 2023 | lexology.com | Stephen Abreu

Click here to watch to the videoStephen Abreu, Sidley partner, talks to Colin Hill, CEO and Co-Founder of AI-powered drug discovery company Aitia, about how the use of AI is revolutionizing the biotech space.